Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: Current evidence and future prospects

Therapeutic Advances in Respiratory Disease

Volumn 9, Issue 6, 2015, Pages 313-326

  Kuk, Kelly ^a   Taylor Cousar, Jennifer L ^b  

^a Exempla Saint Joseph Hospital   (United States)

^b Pulmonary Division   (United States)

Author keywords

corrector; cystic fibrosis; cystic fibrosis transmembrane conductance regulator modulator; ivacaftor; lumacaftor; potentiator

Indexed keywords

BICARBONATE; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; PLACEBO; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN; DRUG COMBINATION; LUMACAFTOR, IVACAFTOR DRUG COMBINATION; QUINOLONE DERIVATIVE; RESPIRATORY TRACT AGENT;

CELL MIGRATION; CELL SURFACE; CFTR GENE; CHEST TIGHTNESS; CHLORIDE TRANSPORT; CLINICAL STUDY; COUGHING; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; DYSPNEA; EPITHELIUM CELL; FORCED EXPIRATORY VOLUME; HEADACHE; HOMOZYGOSITY; HUMAN; LOSS OF FUNCTION MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN STABILITY; RESPIRATORY TRACT DISEASE; REVIEW; STEADY STATE; SYMPTOM; WATER TRANSPORT; DNA MUTATIONAL ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; LUNG; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; TREATMENT OUTCOME;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA MUTATIONAL ANALYSIS; DRUG COMBINATIONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG; MUTATION; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; QUINOLONES; RESPIRATORY SYSTEM AGENTS; TREATMENT OUTCOME;

EID: 84947293530     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815601934     Document Type: Review

References (51)

1. Accurso F. Rowe S. Clancy J. Boyle M. Dunitz J. Durie P. (2010) Effect of Vx-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991–2003.
2. Andersen D. (1938) Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56: 344–399.
3. Barry P. Plant B. Nair A. Bicknell S. Simmonds N. Bell N. (2014) Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. Chest 146: 152–158.
4. Borowitz D. Gelfond D. (2013) Intestinal complications of cystic fibrosis. Curr Opin Pulm Med 19: 676–680.
5. Boyle M. Bell S. Konstan M. McColley S. Rowe S. Rietschel E. (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2: 527–538.
6. Boyle M. De Boeck K. (2013) A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 1: 158–163.
7. CFF (2013) Cystic Fibrosis Foundation National Patient Registry Annual Data Report. Bethesda, MD.
8. CFF (2015) Cystic Fibrosis Foundation. Retrieved from: www.cff.org
9. Cholon D. Quinney N. Fulcher M. Esther C. Jr Das J. Dokholyan N. (2014) Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med 6: 246ra296.
10. Clancy J. Rowe S. Accurso F. Aitken M. Amin R. Ashlock M. (2012) Results of a phase IIa study of VX-809, an investigational CFTR Corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67: 12–18.
11. Davies J. Wainwright C. Canny G. Chilvers M. Howenstine M. Munck A. (2013) Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 187: 1219–1225.
12. De Boeck K. Munck A. Walker S. Faro A. Hiatt P. Gilmartin G. (2014) Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13: 674–680.
13. Denning G. Ostedgaard L. Welsh M. (1992) Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol 118: 551–559.
14. Donaldson S. Bennett W. Zeman K. Knowles M. Tarran R. Boucher R. (2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354: 241–250.
15. Elkins M. Robinson M. Rose B. Harbour C. Moriarty C. Marks G. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229–240.
16. FDA (2015) U. S. Food and Drug Administration Advisory Committee Report. Silver Spring, MD.
17. Flume P. Liou T. Borowitz D. Li H. Yen K. Ordonez C. (2012) Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142: 718–724.
18. Fuchs H. Borowitz D. Christiansen D. Morris E. Nash M. Ramsey B. (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 331: 637–642.
19. Gibson R. Burns J. Ramsey B. (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168: 918–951.
20. Griesenbach U. Alton E. (2013) Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 22: R52–R58.
21. Hebestreit H. Sauer-Heilborn A. Fischer R. Kading M. Mainz J. (2013) Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551d mutation. J Cyst Fibros 12: 599–603.
22. Ikuma M. Welsh M. (2000) Regulation of CFTR Cl- channel gating by ATP binding and hydrolysis. Proc Natl Acad Sci U S A 97: 8675–8680.
23. Kerem B. Rommens J. Buchanan J. Markiewicz D. Cox T. Chakravarti A. (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1073–1080.
24. Kerem E. Reisman J. Corey M. Canny G. Levison H. (1992) Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326: 1187–1191.
25. Konstan M. Byard P. Hoppel C. Davis P. (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332: 848–854.
26. Konstan M. Vandevanter D. Rasouliyan L. Pasta D. Yegin A. Morgan W. (2010) Trends in the use of routine therapies in cystic fibrosis: 1995–2005. Pediatr Pulmonol 45: 1167–1172.
27. Mackenzie T. Gifford A. Sabadosa K. Quinton H. Knapp E. Goss C. (2014) Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med 161: 233–241.
28. McKone E. Borowitz D. Drevinek P. Griese M. Konstan M. Wainwright C. (2014) Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2: 902–910.
29. McNeer N. Anandalingam K. Fields R. Caputo C. Kopic S. Gupta A. (2015) Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. Nat Commun 6: 6952.
30. Oermann C. Retsch-Bogart G. Quittner A. Gibson R. McCoy K. Montgomery A. (2010) An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 45: 1121–1134.
31. Peltz S. Morsy M. Welch E. Jacobson A. (2013) Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 64: 407–425.
32. Quittner A. Modi A. Wainwright C. Otto K. Kirihara J. Montgomery A. (2009) Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 135: 1610–1618.
33. Ramsey B. Davies J. McElvaney N. Tullis E. Bell S. Drevinek P. (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365: 1663–1672.
34. Ramsey B. Pepe M. Quan J. Otto K. Montgomery A. Williams-Warren J. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340: 23–30.
35. Riordan J. Rommens J. Kerem B. Alon N. Rozmahel R. Grzelczak Z. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066–1073.
36. Rommens J. Iannuzzi M. Kerem B. Drumm M. Melmer G. Dean M. (1989) Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245: 1059–1065.
37. Rowe S. Heltshe S. Gonska T. Donaldson S. Borowitz D. Gelfond D. (2014) Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 190: 175–184.
38. Rowe S. Miller S. Sorscher E. (2005) Cystic fibrosis. N Engl J Med 352: 1992–2001.
39. Saiman L. Anstead M. Mayer-Hamblett N. Lands L. Kloster M. Hocevar-Trnka J. (2010) Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303: 1707–1715.
40. Saiman L. Marshall B. Mayer-Hamblett N. Burns J. Quittner A. Cibene D. (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290: 1749–1756.
41. Stick S. Brennan S. Murray C. Douglas T. Von Ungern-Sternberg B. Garratt L. (2009) Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 155: 623–628 e621.
42. Taylor-Cousar J. Niknian M. Gilmartin G. Pilewski J. for the VX11-770-901 Investigators (2015) Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: safety and efficacy in an expanded access program in the United States. J Cyst Fibros. Epub ahead of print 11 February. DOI: 10.1016/j.jcf.2015.01.008.
43. Thomas P. Ko Y. Pedersen P. (1992) Altered protein folding may be the molecular basis of most cases of cystic fibrosis. FEBS Lett 312: 7–9.
44. Toronto, Cystic Fibrosis Centre at the Hospital for Sick Children. (2015) Cystic fibrosis mutation database. Retrieved from: http://www.genet.sickkids.on.ca/app
45. Van Goor F. Hadida S. Grootenhuis P. Burton B. Cao D. Neuberger T. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106: 18825–18830.
46. Van Goor F. Hadida S. Grootenhuis P. Burton B. Stack J. Straley K. (2011) Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 108: 18843–18848.
47. Van Goor F. Yu H. Burton B. Huang C. Hoffman B. (2012) Ivacaftor potentiates multiple mutant cystic fibrosis transconductance regulator (CFTR) forms. Pediatr Pulmonol 47: 233.
48. Veit G. Avramescu R. Perdomo D. Phuan P. Bagdany M. Apaja P. (2014) Some gating Ppotentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med 6: 246ra297.
49. Vertex Pharmaceuticals (2015) Kalydeco Prescribing Information. Retrieved form: http://pi.vrtx.com/files/uspi_ivacaftor.pdf
50. Wainwright C. Elborn J. Ramsey B. Marigowda G. Huang X. Cipolli M. (2015) Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373(3): 220–231.
51. Yu H. Burton B. Huang C. Worley J. Cao D. Johnson J. Jr. (2012) Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 11: 237–245.